Oramed Pharmaceuticals Stock Analysis
| ORMP Stock | USD 3.23 0.06 1.89% |
IPO Date 21st of April 2006 | 200 Day MA 2.4937 | 50 Day MA 3.1716 | Beta 1.308 |
Oramed Pharmaceuticals holds a debt-to-equity ratio of 0.006. At this time, Oramed Pharmaceuticals' Net Debt To EBITDA is relatively stable compared to the past year. As of 02/13/2026, Long Term Debt To Capitalization is likely to grow to 0, though Net Debt is likely to grow to (46.2 M). Oramed Pharmaceuticals' financial risk is the risk to Oramed Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Oramed Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Oramed Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Oramed Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Oramed Pharmaceuticals' stakeholders.
For many companies, including Oramed Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Oramed Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Oramed Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.6383 | Enterprise Value Ebitda 0.5244 | Price Sales 63.1594 | Shares Float 29.3 M | Wall Street Target Price 3.25 |
Oramed Pharmaceuticals is undervalued with Real Value of 3.47 and Target Price of 3.25. The main objective of Oramed Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Oramed Pharmaceuticals is worth, separate from its market price. There are two main types of Oramed Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Oramed Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Oramed Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Oramed Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Oramed Stock Analysis Notes
About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals last dividend was issued on the 16th of January 2026. The entity had 1:12 split on the 23rd of January 2013. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. Oramed Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about Oramed Pharmaceuticals contact Nadav Esq at 844 967 2633 or learn more at https://www.oramed.com.Oramed Pharmaceuticals Investment Alerts
| Oramed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.06 M) with profit before overhead, payroll, taxes, and interest of 13 K. | |
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oramed Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| On 26th of January 2026 Oramed Pharmaceuticals paid $ 0.25 per share dividend to its current shareholders | |
| Latest headline from news.google.com: NNDM Stock In Focus Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up - Stocktwits |
Oramed Largest EPS Surprises
Earnings surprises can significantly impact Oramed Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | 0.02 | 0.04 | 0.02 | 100 | ||
2016-01-13 | 2015-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2014-01-14 | 2013-12-31 | -0.16 | -0.14 | 0.02 | 12 |
Oramed Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Oramed Pharmaceuticals' ESG score is a quantitative measure that evaluates Oramed Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Oramed Pharmaceuticals' operations that may have significant financial implications and affect Oramed Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Oramed Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 60.4 K | Susquehanna International Group, Llp | 2025-06-30 | 48.4 K | Royal Bank Of Canada | 2025-06-30 | 47.6 K | Squarepoint Ops Llc | 2025-06-30 | 46.1 K | Rbf Llc | 2025-06-30 | 42.9 K | Jane Street Group Llc | 2025-06-30 | 42.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 32.1 K | Geode Capital Management, Llc | 2025-06-30 | 24.3 K | Pnc Financial Services Group Inc | 2025-06-30 | 23.2 K | Bml Capital Management Llc | 2025-06-30 | 3.1 M | Murchinson Ltd. | 2025-06-30 | 1.8 M |
Oramed Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 126.32 M.Oramed Profitablity
The company has Profit Margin (PM) of 21.93 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (6.51) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $6.51.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.12) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.11) | (0.12) | |
| Return On Equity | (0.13) | (0.12) |
Management Efficiency
Oramed Pharmaceuticals has return on total asset (ROA) of (0.0422) % which means that it has lost $0.0422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2448 %, meaning that it created $0.2448 on every $100 dollars invested by stockholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/13/2026, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to drop to -0.08. At this time, Oramed Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 02/13/2026, Non Current Liabilities Other is likely to grow to about 83 K, while Total Current Liabilities is likely to drop slightly above 5.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.20 | 3.36 | |
| Tangible Book Value Per Share | 3.20 | 3.36 | |
| Enterprise Value Over EBITDA | (2.71) | (2.84) | |
| Price Book Value Ratio | 0.61 | 0.64 | |
| Enterprise Value Multiple | (2.71) | (2.84) | |
| Price Fair Value | 0.61 | 0.64 | |
| Enterprise Value | 40.3 M | 80.5 M |
Oramed Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin | Profit Margin | Forward Dividend Yield 0.0767 | Beta 1.308 | Return On Assets |
Technical Drivers
As of the 13th of February 2026, Oramed Pharmaceuticals holds the Risk Adjusted Performance of 0.1716, semi deviation of 2.09, and Coefficient Of Variation of 495.61. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them.Oramed Pharmaceuticals Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Oramed Pharmaceuticals price series with the more recent values given greater weights.
Oramed Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oramed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oramed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oramed Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oramed Pharmaceuticals Outstanding Bonds
Oramed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oramed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oramed bonds can be classified according to their maturity, which is the date when Oramed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Oramed Pharmaceuticals Predictive Daily Indicators
Oramed Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oramed Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3401.84 | |||
| Daily Balance Of Power | 0.3333 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 3.24 | |||
| Day Typical Price | 3.24 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.06 |
Oramed Pharmaceuticals Forecast Models
Oramed Pharmaceuticals' time-series forecasting models are one of many Oramed Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oramed Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Oramed Pharmaceuticals Bond Ratings
Oramed Pharmaceuticals financial ratings play a critical role in determining how much Oramed Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Oramed Pharmaceuticals' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (4.85) | Unlikely Manipulator | View |
Oramed Pharmaceuticals Debt to Cash Allocation
Oramed Pharmaceuticals currently holds 372 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Oramed Pharmaceuticals has a current ratio of 20.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oramed Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.Oramed Pharmaceuticals Total Current Liabilities Over Time
Oramed Pharmaceuticals Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Oramed Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Oramed Pharmaceuticals Debt Ratio | 0.2 |
Oramed Pharmaceuticals Corporate Bonds Issued
Oramed Net Debt
About Oramed Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oramed Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oramed shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oramed Pharmaceuticals. By using and applying Oramed Stock analysis, traders can create a robust methodology for identifying Oramed entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 3.42 | 3.59 | |
| Operating Profit Margin | (13.53) | (14.21) | |
| Net Profit Margin | 3.71 | 3.90 | |
| Gross Profit Margin | 0.87 | 0.65 |
Current Oramed Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oramed analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oramed analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 3.25 | Hold | 1 | Odds |
Most Oramed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Oramed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Oramed Pharmaceuticals, talking to its executives and customers, or listening to Oramed conference calls.
Oramed Stock Analysis Indicators
Oramed Pharmaceuticals stock analysis indicators help investors evaluate how Oramed Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oramed Pharmaceuticals shares will generate the highest return on investment. By understating and applying Oramed Pharmaceuticals stock analysis, traders can identify Oramed Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 9.1 M | |
| Total Stockholder Equity | 146.3 M | |
| Net Borrowings | -49.5 M | |
| Capital Lease Obligations | 372 K | |
| Property Plant And Equipment Net | 1.1 M | |
| Cash And Short Term Investments | 141.9 M | |
| Cash | 54.4 M | |
| 50 Day M A | 3.1716 | |
| Net Interest Income | 4.1 M | |
| Total Current Liabilities | 5.7 M | |
| Investments | 105.8 M | |
| Interest Expense | 853 K | |
| Stock Based Compensation | 4.1 M | |
| Common Stock Shares Outstanding | 40.8 M | |
| Total Cashflows From Investing Activities | 105.8 M | |
| Tax Provision | 3.2 M | |
| Quarterly Earnings Growth Y O Y | 0.409 | |
| Other Current Assets | 1.3 M | |
| Accounts Payable | 789 K | |
| Net Debt | -54 M | |
| Other Operating Expenses | 12.8 M | |
| Non Current Assets Total | 12.1 M | |
| Liabilities And Stockholders Equity | 155.3 M | |
| Non Currrent Assets Other | 34 K |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.